Maelstrom Research Staging | SMSC_Followup

SMSC_Followup_48months

Networks -

Variables -

Population

SMSC population

The population is composed of patients in Switzerland who are diagnosed with relapsing-remitting, primary progressive, or secondary progressive MS.

Selection Criteria

Newborns

Twins

Countries

Switzerland

Territory

Aarau, Basel, Berne, Geneva, Lausanne, Lugano, St. Gallen, Zurich

Ethnic Origin

Health Status

Patients must be diagnosed with relapsing-remitting, primary progressive, or secondary progressive MS according to the 2010 revised McDonald criteria or previously established criteria (McDonald or Poser). Patients diagnosed with a clinically isolated syndrome, radiologically isolated syndrome, or neuromyelitis optica can also be included.

Other Criteria

Patients who do not receive immunomodulatory (DMD) treatment, who need to begin or switch a DMD as judged by the treating physician, who start or switch a DMD, or who are already treated with natalizumab or fingolimod are included.

Recruitment

Sources of recruitment

Specific population

Specific Population

Clinic patients

Supplementary Information

Participants are recruited from any of the eight study centres: the Cantonal Hospital of Aarau, the University Hospitals of Basel, Berne, Geneva, Lausanne and Zurich, the Regional Hospital of Lugano, and the Cantonal Hospital of St. Gallen.

Number of Participants

Number of Participants: No Limit
Number of Participants with Biological Samples: No Limit
Supplementary Information about selection criteria

More info

Data Collection Event

SMSC - Follow-up 48 months

Information is collected about sociodemographic characteristics (sex, date of birth, ethnicity), pregnancy history, family history of MS, date of first MS symptom, date of the second relapse, number of relapses in the last two years, date of diagnosis, date of start of progression (if applicable), DMDs (initiation or interruption, DMD-related adverse events), concomitant medical conditions and medications. A standardized clinical assessment for disability progression is conducted using the Expanded Disability Status Scale (EDSS). An optional MRI scan is taken. Blood samples are collected. Cerebrospinal fluid is collected from a small subsample of participants.

More info

Collected Dataset / SMSC_Followup_48months

SMSC_Followup_48months

Population

SMSC population

Data Collection Event

SMSC - Follow-up 48 months

Files

Variables Classifications